Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Unknown 2Recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 143Thoracic 45Head & Neck 19Lymphoid 9Gynecologic 7Breast 7Genitourinary 4CNS 4Tumor-Agnostic 3Sarcoma 3Endocrine 3Other neoplasm 2NET 2Other solid neoplasm 1Myeloid 1Dermatologic 1

Conditions

Neuroendocrine Tumors 2Carcinoma, Neuroendocrine 2Pancreatic Neoplasms 1

Interventions

Everolimus 27pembrolizumab 25Temozolomide 24lutetium Lu 177 dotatate 22Nivolumab 18Magnetic Resonance Spectroscopy 18lenvatinib 17cabozantinib 17Cisplatin 16Sunitinib 15Capecitabine 14Bevacizumab 14Specimen Handling 12Sorafenib 12trametinib 10Ipilimumab 10Etoposide 10pasireotide 9dabrafenib 9Paclitaxel 9Carboplatin 8pazopanib 7lanreotide 7Octreotide 7Fluorodeoxyglucose F18 7anlotinib 6Irinotecan 6Injections 6Doxorubicin 6surufatinib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × sintilimab × Endocrine × Clear all
NCT05165407 2025-03-14

NESSIE

Peking University

Phase 2 Recruiting
30 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT05627427 2022-11-25

Multi-cohort Study of Surufatinib Plus Sintilimab in Metastatic NEN and Pancreatic Carcinoma Who Failed Standard Chemotherapy

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Unknown
60 enrolled
EndocrineGastrointestinal

Pancreatic Neoplasms, Carcinoma, Neuroendocrine

NCT05113355 2021-11-24

Chidamide Plus Sintilimab for Chemotherapy-refractory Advanced High-grade Neuroendocrine Neoplasm

Peking Union Medical College Hospital

Phase 2 Unknown
23 enrolled
EndocrineNET

Carcinoma, Neuroendocrine, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡